http://www.journalmyhealth.com/

Journal My Health, Philadelphia, PA (2026)

10/28/2026

Christina Applegate spent five years living with an MS diagnosis. This week she shared that she doesn’t have MS. Her symptoms haven’t gone anywhere. In her words, she’s back at square one.

I hear that phrase from women all the time.

She’s not an outlier. Research shared alongside her story found that nearly 1 in 5 people diagnosed with MS didn’t fully meet the criteria. There’s no single test for MS, and many of its symptoms show up in other conditions too.

Here’s the part that rarely comes up: menopause.

Fatigue. Brain fog. Poor sleep. Mood changes. Bladder issues. Those are MS symptoms. They’re also perimenopause symptoms.

About a third of women with MS are peri- or postmenopausal. One study found that women who reached menopause before their MS diagnosis waited longer for that diagnosis, close to 9 years on average compared with about 5.5. A 2026 review found that two-thirds of women with MS had never talked to a clinician about menopause at all.

It’s important to remember that our health is shaped by processes that unfold over time. Some are natural life stages, like perimenopause and menopause. Some are disease processes, like MS. At certain points, two very different processes can look almost the same. A single appointment captures one moment. Only data collected over time shows how things are actually changing.

That’s how misdiagnosis happens. Perimenopause and MS can be mistaken for each other, and the wrong label can lead to the wrong treatment.

That’s what Journal My Health is built for. Daily tracking turns “something’s off” into a timeline you can bring to your doctor. It doesn’t diagnose. It gives the conversation better information to work with.

It’s also why our research focuses on women managing chronic and autoimmune conditions through the hormonal transition.

Thank you to for discussing this with us.

10/14/2026

The data gap that matters most in chronic-condition tracking isn't missing days overall — it's missing the worst days specifically.

People are most likely to skip logging exactly when they're flaring, which means the data set silently excludes the moments that would be most clinically and personally useful. Tools that lower the bar to a single tap — no writing required — see meaningfully better completion on high-symptom days.

That's a detail worth asking about if you're comparing tracking tools for a benefits program.

Let's talk if you want to dig into what "low-friction on bad days" actually looks like in practice.

10/07/2026

The wellness benefits that get used aren't the ones with the most features — they're the ones with the lowest friction.

A 30-second daily log will always outperform a comprehensive but cumbersome tool, because adherence beats sophistication when it comes to real-world data collection.

This is a design principle worth pressure-testing in any chronic-condition or wellness benefit you're considering: how much effort does day 1 actually require, and does that effort stay low through week 4?

09/30/2026

Engagement drop-off in the first two weeks is the single biggest threat to any self-tracked wellness benefit — and it's rarely about the tool.

It's about the lag between effort and payoff. Employees start logging symptoms and don't see anything meaningful for a week or more, so they assume it isn't working and stop. The organizations that get the most value from tools like Journal My Health are the ones that set expectations upfront: this is a 2-3 week investment before the insight shows up, not a same-day dashboard.

If you're evaluating a self-tracking benefit, ask the vendor how they handle the early drop-off window. It matters more than the feature list.

09/16/2026

Engagement drop-off in the first two weeks is the single biggest threat to any self-tracked wellness benefit — and it's rarely about the tool.

It's about the lag between effort and payoff. Employees start logging symptoms and don't see anything meaningful for a week or more, so they assume it isn't working and stop. The organizations that get the most value from tools like Journal My Health are the ones that set expectations upfront: this is a 2-3 week investment before the insight shows up, not a same-day dashboard.

If you're evaluating a self-tracking benefit, ask the vendor how they handle the early drop-off window. It matters more than the feature list.

09/02/2026

A month of pattern-insight data can change more than an individual conversation — it can change how an organization thinks about chronic-condition support.

Over the past few weeks, we've talked about the overlap between autoimmune conditions and menopause, why real-world tracking data matters, and how it helps women walk into medical appointments prepared instead of dismissed. That same data, aggregated and anonymized, is exactly the kind of signal employers and health plans need to design better, earlier support.

Journal My Health is currently exploring partnerships with organizations who want to be ahead of this curve.

If that's you, let's set up time to talk.

08/26/2026

Real-world symptom data is one of the most underused inputs in chronic-condition benefits design.

Most benefits programs are built around claims data — after the fact, after the cost has already landed. Journal My Health takes a different approach: helping individuals build a day-to-day picture of their own patterns, in plain, non-clinical language they can act on immediately.

For employers and health plans evaluating where to invest in chronic-condition support, that's a signal worth paying attention to — a low-cost, low-friction way to help employees self-advocate before symptoms become a bigger (and more expensive) problem.

If you're rethinking what "chronic condition support" looks like for your team, I'd love to compare notes.

08/19/2026

What if the simplest benefit you could offer women navigating menopause and autoimmune symptoms wasn't a new specialist — it was a way to help them advocate for themselves?

Journal My Health isn't a clinical tool, and it's not trying to replace care. It's a wellness platform that helps women build a clear, pattern-based picture of their own health — the kind of specific, day-to-day insight that makes existing medical appointments more productive, faster.

For organizations exploring low-cost, high-impact additions to their benefits mix, this is worth a look: something employees can start using immediately, with no clinical overhead, that directly supports better conversations with the providers they already see.

Open to a short conversation about what a pilot could look like for your team?
Happy to share more.

08/12/2026

Every HR leader is thinking about chronic condition costs. Almost none are thinking about the autoimmune-menopause overlap.

Millions of women in the workforce are navigating both at once — and the symptom overlap makes it harder to identify, harder to manage, and easier to dismiss as "just stress." The result: absenteeism, reduced productivity, and employees who don't have the language to advocate for what they need.

At Journal My Health, we're building tools that help women identify their own patterns — turning "I don't feel right" into something specific enough to act on. That's not just better for the individual. It's a smarter, lower-cost starting point for any organization thinking about chronic-condition support.

Curious what this could look like as part of a benefits conversation? Let's talk.

08/05/2026

A new analysis presented at The Menopause Society's 2025 Annual Meeting looked at nearly 1.8 million postmenopausal women — and found hormone therapy use was linked to a higher incidence of autoimmune disease.

That's a big, unsettling headline for anyone already navigating an autoimmune condition through menopause.

But the study's own lead author, Dr. Xuezhi (Daniel) Jiang of Drexel University College of Medicine, was careful to add context: the actual increase in absolute risk is relatively small and varies by condition, and because it's a retrospective database study, more research is needed before drawing firm conclusions. He was clear that hormone therapy remains a safe and important option for many women when used appropriately.

The throughline from both Dr. Jiang and The Menopause Society's medical director, Dr. Stephanie Faubion: this needs to be individualized. Not a blanket yes or no — a decision based on each woman's own body.

The problem is, most women walk into that conversation with nothing individual to bring. No data on how their body actually responds to sleep, stress, weather, or flares before they even start a new treatment. Just a headline, a worry, and a 15-minute appointment.

That's the gap Journal My Health exists to close. Daily tracking turns "I'm not sure how I'll react" into a real pattern — something specific enough to actually inform an individualized decision, instead of guessing from a population-level study.

Evidence, not guesswork. That's what individualized care requires.